Skip to main content
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
A Plain Language Summary of the SEQUOIA-HCM Study: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
The Effect of Omecamtiv Mecarbil on Outcomes Analysed Using the Win Ratio: an Exploratory Analysis of GALACTIC-HF
Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical Region
Associations Between Age and Sex and Cardiovascular Outcomes in Patients With Non-Obstructive Hypertrophic Cardiomyopathy
Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms
Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial
Long-term Healthcare Costs and Utilization Among Patients With Non-Obstructive Hypertrophic Cardiomyopathy
Clinical and Economic Burden of Non-Obstructive Hypertrophic Cardiomyopathy: A Literature Review
Assessing Differences in Clinical Burden Across Payers for Non-Obstructive Hypertrophic Cardiomyopathy